Addex Therapeutics Ltd is a clinical-stage pharmaceutical company. It is focused on the development and commercialization of small molecule drugs for neurological disorders. The company's lead drug candidate includes dipraglurant, ADX71149 which are in clinical stage. Its Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson's disease and mGlu3 PAM for neurodegenerative disorders. GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Addex Therapeutics Ltd is based in Geneva, Switzerland....
+See More2019-09-01 10:31:00 Sunday ET
Most artificial intelligence applications cannot figure out the intricate nuances of natural language and facial recognition. These intricate nuances repres
2023-06-19 10:31:00 Monday ET
A brief biography of Dr Andy Yeh (PhD, MFE, MMS, BMS, FRM, and USPTO patent accreditation) Dr Andy Yeh is responsible for ensuring maximum sustainable me
2019-08-12 07:30:00 Monday ET
Facebook reaches a $5 billion settlement with the Federal Trade Commission over Cambridge Analytica user privacy violations. The Federal Trade Commission (F
2018-08-15 14:40:00 Wednesday ET
Senator Elizabeth Warren advocates the alternative view that most U.S. trade deals serve corporate interests over workers, customers, and suppliers etc. She
2018-08-07 07:33:00 Tuesday ET
President Trump sounds smart when he comes up with a fresh plan to retire $15 trillion national debt. This plan entails taxing American consumers and produc
2018-07-21 13:35:00 Saturday ET
President Trump supports a bipartisan bill or the Foreign Investment Risk Review Modernization Act (FIRRMA), which effectively broadens the jurisdiction of